Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (not Ocugen, Inc.) reports on the 2018 Annual Meeting of Stockholders held on June 15, 2018. The document details the results of shareholder votes regarding director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 28,687,412 shares entitled to vote, 25,167,523 shares (approximately 87.7%) were represented, constituting a quorum.
Proposal 1: Election of Directors
Stockholders elected two Class I directors for a three-year term ending in 2021. The voting results were identical for both nominees:
| Director | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Joshua Baltzell | 14,815,328 | 1,699,287 | 8,652,908 |
| Kevin Rakin | 14,815,328 | 1,699,287 | 8,652,908 |
Proposal 2: Ratification of Auditor
Stockholders ratified the selection of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| Votes For | Votes Against | Votes Abstaining |
|---|---|---|
| 25,007,759 | 153,197 | 6,567 |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. For further details on the proposals, the filing references the definitive proxy statement on Schedule 14A filed on April 26, 2018.
Investor Verification Checklist
- Verify the company name is Histogenics Corporation, not Ocugen, Inc., as indicated in the metadata request.
- Confirm the high number of broker non-votes (8,652,908) relative to votes cast for directors.
- Review the Schedule 14A proxy statement filed on April 26, 2018, for detailed background on the director nominees and auditor selection.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.